Latest news
Respiratorius and Iconovo collaborate on inhalation product for COPD
Biostock published May 21th an article about Iconovo that can be found in its entirety below
The two Lund-based development companies Respiratorius…
Iconovo sets ambitious financial targets for 2026
Iconovo AB (publ), which develops complete inhalation products for a global market, today announces its five-year goals for the business. By…
Press releases
Feb 08, 2023, 17:32
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 08, 2023, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 03, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 03, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Jan 26, 2023, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Jan 11, 2023, 08:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se